Immunophotonics Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President have announced a partnership that will combine use of Immunophotonics’ lead asset, IP-001 and AngioDynamics’ ablation devices to explore the power of ablation in combination with immunotherapy for the treatment of solid tumor cancers.  This collaborative effort extends to a partnership with the Cancer Center Amsterdam at Amsterdam University Medical Center (Amsterdam UMC) in the Netherlands.

Special recognition is extended to Danielle Vos and Martijn Meijerink, MD, PhD at Amsterdam UMC in the Netherlands for their pivotal roles in conducting a clinical trial to evaluate the efficacy of this combinational treatment to further propel the field of Interventional Immuno-Oncology™.

Read more: Official Press Release